A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19

NCT04402060 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID
Covid-19
Coronavirus
Coronavirus Infection
Severe Acute Respiratory Syndrome
Severe Acute Respiratory Syndrome Coronavirus 2
Sars-CoV2
Ards
Acute Respiratory Distress Syndrome

Interventions

DRUG: APL-9
OTHER: Vehicle Control

Sponsor

Apellis Pharmaceuticals, Inc.